Cancer thrives by hijacking the body's own basic survival systems, making it hard to attack tumors without collateral damage ...

In an effort to foster progress in cancer research, the National Institute of Standards and Technology (NIST) is releasing detailed and comprehensive data about the entire genetic content of a ...

In August, Zongertinib received FDA approval for previously treated HER2-mutant NSCLC. It now shows efficacy in first-line ...

Researchers in Sweden are testing a 250-year-old medicine in patients with one of the world's deadliest cancers.

Imagine that two women have breast cancer with the same subtype: hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). They’re the same age, weight, and height ...

Griffith University researchers have shown that the shape and surface chemistry of microscopic "re-entrant" structures—tiny overhanging caps arranged like mushroom tops—can tune how cancer cells stick ...

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra (tarlatamab-dlle) was found to improve overall ...

Akeso and Summit Therapeutics have shared the full data from the HARMONi-6 trial of PD-1xVEGF bispecific ivonescimab as a ...